CTD Clinical Follow-Up Still Needed For Breast Implants, FDA Maintains
This article was originally published in The Gray Sheet
Executive Summary
Breast implant patients should be monitored for symptoms of connective tissue disease annually for a minimum of 10 years post-implantation, FDA advises in final guidance to be issued Aug. 13.